Search

Your search keyword '"Basak, G.W."' showing total 4 results
Start Over Author "Basak, G.W." Journal bone marrow transplantation
4 results on '"Basak, G.W."'

1. The EBMT activity survey on hematopoietic-cell transplantation and cellular therapy 2018: CAR-T's come into focus

Author

Passweg, J.R., Baldomero, H., Chabannon, C., Basak, G.W., Corbacioglu, S., Duarte, R., Dolstra, H., Lankester, A.C., Mohty, M., Montoto, S., Latour, R.P. de, Snowden, J.A., Styczynski, J., Yakoub-Agha, I., Kroger, N., European Soc Blood Marrow Transpla, UAM. Departamento de Medicina, University Hospital Basel [Basel], Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Medical University of Warsaw - Poland, Universität Regensburg (UR), Hospital Universitario Puerta de Hierro-Majadahonda [Madrid, Spain], Radboud University Medical Center [Nijmegen], Leiden University Medical Center (LUMC), Centre de Recherche Saint-Antoine (CR Saint-Antoine), Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Barts Health NHS Trust [London, UK], Hopital Saint-Louis [AP-HP] (AP-HP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Department of Haematology & Department of Oncology, NHS & University of Sheffield, University of Technology and Life Sciences [ Bydgoszcz], CHU Lille, University Hospital Hamburg-Eppendorf, Universitaetsklinikum Hamburg-Eppendorf = University Medical Center Hamburg-Eppendorf [Hamburg] (UKE), Centre de Recherche Saint-Antoine (CRSA), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), and Gestionnaire, HAL Sorbonne Université 5

Subjects
[SDV.MHEP.HEM] Life Sciences [q-bio]/Human health and pathology/Hematology, Oncology, medicine.medical_specialty, Myeloid, Medicina, Cancer development and immune defence Radboud Institute for Molecular Life Sciences [Radboudumc 2], medicine.medical_treatment, Hematopoietic stem cell transplantation, Transplantation, Autologous, Article, Cell therapy, 03 medical and health sciences, 0302 clinical medicine, Internal medicine, hemic and lymphatic diseases, Medicine, Leukaemia, Humans, Transplantation, Homologous, Aplastic anemia, Cellular therapies, Transplantation, Haematological cancer, Receptors, Chimeric Antigen, European Society for Blood and Marrow Transplantation (EBMT), business.industry, Multiple sclerosis, Hematopoietic Stem Cell Transplantation, [SDV.MHEP.HEM]Life Sciences [q-bio]/Human health and pathology/Hematology, Hematology, medicine.disease, Lymphoid malignancies, 3. Good health, Europe, Haematopoiesis, medicine.anatomical_structure, 030220 oncology & carcinogenesis, Hematopoietic-cell transplantation (HCT), Car t cells, business, 030215 immunology
Abstract

Hematopoietic-cell transplantation (HCT) is widely used for acquired and congenital disorders of the hematopoietic system. Number of transplants performed in Europe and associated countries continues to rise with 47,468 HCT in 42,901 patients [19,630 allogeneic (41%) and 27,838 autologous (59%)] reported by 701 centers in 50 countries in 2018. Main indications were myeloid malignancies 10,679 (25%; 97% allogeneic), lymphoid malignancies 27,318 (64%; 20% allogeneic), solid tumors 1625 (4%; 2.9% allogeneic), and nonmalignant disorders 3063 (7%; 81% allogeneic). This year’s analysis focuses on cellular therapies with the marked growth in CAR T-cell therapies from 151 in 2017 to 301 patients reported in 2018. Other cellular therapy numbers show less significant changes. Important trends in HCT include a 49% increase in allogeneic HCT for chronic phase CML (although transplant numbers remain low) and a 24% increase in aplastic anemia. In autologous HCT, there is an ongoing increase in autoimmune diseases (by 19%), predominantly due to activity in multiple sclerosis. This annual report reflects current activity and highlights important trends, useful for health care planning.

Published
2020

2. Chronic graft-versus-host disease features in double unit cord blood transplantation according to National Institutes of Health 2005 cGVHD Consensus criteria

Author

Hayashi, H., Ruggeri, A., Volt, F., Cornelissen, J.J., Socie, G., Sengeloev, H., Michallet, M., Karakasis, D., Petersen, E., Cahn, J.Y., Veelken, H., Mercier, M., Rohrlich, P.S., Rafii, H., Kenzey, C., Xavier, E., Duarte, R.F., Basak, G.W., Rocha, V., Gluckman, E., Eurocord Complications Quality, and Hematology

Subjects
Adult, Lung Diseases, Male, medicine.medical_specialty, Consensus, Adolescent, CONSENSO, Graft vs Host Disease, Consensus criteria, Severity of Illness Index, Young Adult, 03 medical and health sciences, 0302 clinical medicine, Text mining, Internal medicine, medicine, Humans, Cord blood transplantation, Aged, Retrospective Studies, Transplantation, business.industry, Liver Diseases, Hematology, Middle Aged, medicine.disease, United States, Graft-versus-host disease, National Institutes of Health (U.S.), 030220 oncology & carcinogenesis, Chronic Disease, Female, Cord Blood Stem Cell Transplantation, business, 030215 immunology
Published
2018

3. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders : current practice in Europe, 2019

Author

Duarte, R.F., Labopin, M., Bader, P., Basak, G.W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., Genneryl, A.R., Kuball, J., Lankester, A.C., Lanza, F., Montoto, S., Nagler, A., Latour, R.P. de, Snowden, J.A., Styczynski, J., Yakoub-Agha, I., Kroger, N., Mohty, M., Albert, M., Alexander, T., Averbuch, D., Baron, F., Bazarbachi, E., Beksac, M., Brissot, E., Bug, G., Cesaro, S., Chalandon, Y., Ciceri, F., Czerw, T., Dazzi, F., Esteve, J., Fleischhauer, K., Garderet, L., Giebel, S., Gil, L., Gilleece, M., Gorin, N.C., Hayden, P., Halter, J., Boluda, J.C.H., Hudecek, M., Kleinschmidt, K., Kenyon, M., Koenecke, C., Locatelli, F., Malard, F., McLornan, D., Mikulska, M., Murray, J., Onida, F., Pedrazzoli, P., Penack, O., Peric, Z., Risitano, A., Robin, M., Robinson, S., Ruggeri, A., Sanz, J., Savani, B., Schetelig, J., Schied, C., Schmid, C., Schoemans, H., Schonland, S., Sharrack, B., Shouval, R., Spyridonidis, A., Toubert, A., Tourniac, O., Urbano-Ispizua, A., Vago, L., Gelder, M. van, Verhoeven, B., Versluis, J., Wietten, L., Willasch, A., European Soc Blood Marrow Transpla, Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., Gennery, A. R., Kuball, J., Lankester, A. C., Lanza, F., Montoto, S., Nagler, A., Peffault de Latour, R., Snowden, J. A., Styczynski, J., Yakoub-Agha, I., Kroger, N., Mohty, M, and on behalf of the European Society forBlood and Marrow Transplantation, (EBMT)

Subjects
medicine.medical_specialty, Transplantation Conditioning, medicine.medical_treatment, MEDLINE, Disease, Hematopoietic stem cell transplantation, History, 21st Century, NO, 03 medical and health sciences, 0302 clinical medicine, Neoplasms, medicine, Humans, Intensive care medicine, Multiple myeloma, Accreditation, Transplantation, business.industry, Hematopoietic Stem Cell Transplantation, Hematology, medicine.disease, Hematologic Diseases, Europe, Immune System Diseases, Hematologic disease, 030220 oncology & carcinogenesis, business, 030215 immunology
Abstract

This is the seventh special EBMT report on the indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders. Our aim is to provide general guidance on transplant indications according to prevailing clinical practice in EBMT countries and centres. In order to inform patient decisions, these recommendations must be considered together with the risk of the disease, the risk of the transplant procedure and the results of non-transplant strategies. In over two decades since the first report, the EBMT indications manuscripts have incorporated changes in transplant practice coming from scientific and technical developments in the field. In this same period, the establishment of JACIE accreditation has promoted high quality and led to improved outcomes of patient and donor care and laboratory performance in transplantation and cellular therapy. An updated report with operating definitions, revised indications and an additional set of data with overall survival at 1 year and non-relapse mortality at day 100 after transplant in the commonest standard-of-care indications is presented. Additional efforts are currently underway to enable EBMT member centres to benchmark their risk-adapted outcomes as part of the Registry upgrade Project 2020 against national and/or international outcome data.

Published
2019

4. Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF

Author

Francesco Lanza, J. F. Apperley, Rafael F. Duarte, Kai Hübel, K. Douglas, Wieslaw Wiktor-Jedrzejczak, Ozren Jakšić, Catarina Geraldes, Zdenek Koristek, Gabor Mikala, Nina Worel, Mohamad Mohty, Ian H Gabriel, Roberto M. Lemoli, Grzegorz W. Basak, Dominik Selleslag, Basak G.W., Wiktor Jedrzejczak W., Apperley J.F., Douglas K.W., Gabriel I.H., Geraldes C., Hübel K., Jaksic O., Koristek Z., Lanza F., Lemoli R., Mikala G., Selleslag D., Worel N., Mohty M., and Duarte R.F.

Subjects
Oncology, Male, Benzylamines, Lymphoma, Stem cell mobilization, Cyclams, Body Mass Index, 0302 clinical medicine, Adult, Aged, Aged, 80 and over, Contraindications, Female, Granulocyte Colony-Stimulating Factor, Hematopoietic Stem Cell Mobilization, Heterocyclic Compounds, Hodgkin Disease, Humans, Lymphoma, Non-Hodgkin, Middle Aged, Multiple Myeloma, Obesity, Overweight, Retrospective Studies, Thinness, Young Adult, 80 and over, Young adult, Hematology, 3. Good health, Granulocyte colony-stimulating factor, 030220 oncology & carcinogenesis, medicine.drug, medicine.medical_specialty, Motility, Non-Hodgkin, G-CSF, NO, 03 medical and health sciences, BMI, Internal medicine, medicine, Transplantation, business.industry, Plerixafor, Stem Cell Mobilization, nutritional and metabolic diseases, Retrospective cohort study, medicine.disease, Immunology, business, Body mass index, 030215 immunology
Abstract

Higher BMI is not a barrier to stem cell mobilization with standard doses of plerixafor and G-CSF.

Published
2011

Catalog

Books, media, physical & digital resources
See catalog results